1. Home
  2. HOFT vs KLRS Comparison

HOFT vs KLRS Comparison

Compare HOFT & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hooker Furnishings Corporation

HOFT

Hooker Furnishings Corporation

N/A

Current Price

$12.09

Market Cap

144.6M

ML Signal

N/A

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

N/A

Current Price

$4.17

Market Cap

117.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HOFT
KLRS
Founded
1924
2019
Country
United States
United States
Employees
N/A
20
Industry
Home Furnishings
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
144.6M
117.1M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
HOFT
KLRS
Price
$12.09
$4.17
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
22.0K
85.4K
Earning Date
04-16-2026
05-13-2026
Dividend Yield
3.79%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$278,139,000.00
N/A
Revenue This Year
$17.37
N/A
Revenue Next Year
$9.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.62
$2.14
52 Week High
$15.99
$11.88

Technical Indicators

Market Signals
Indicator
HOFT
KLRS
Relative Strength Index (RSI) 43.93 31.92
Support Level $11.97 $3.49
Resistance Level $13.63 $5.43
Average True Range (ATR) 0.78 0.36
MACD -0.03 -0.02
Stochastic Oscillator 10.00 4.63

Price Performance

Historical Comparison
HOFT
KLRS

About HOFT Hooker Furnishings Corporation

Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: